Compare IPCA Labs with Orchid Chemicals - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs ORCHID PHARMA LTD - Comparison Results

IPCA LABS     Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

ORCHID PHARMA LTD 
   Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS ORCHID PHARMA LTD IPCA LABS/
ORCHID PHARMA LTD
 
P/E (TTM) x 22.9 -0.5 - View Chart
P/BV x 4.4 0.1 3,774.2% View Chart
Dividend Yield % 0.1 0.0 -  

Financials

 IPCA LABS   ORCHID PHARMA LTD
EQUITY SHARE DATA
    IPCA LABS
Mar-18
ORCHID PHARMA LTD
Sep-13
IPCA LABS/
ORCHID PHARMA LTD
5-Yr Chart
Click to enlarge
High Rs695194 358.5%   
Low Rs40035 1,142.9%   
Sales per share (Unadj.) Rs260.2276.5 94.1%  
Earnings per share (Unadj.) Rs19.0-79.2 -24.0%  
Cash flow per share (Unadj.) Rs33.1-43.5 -76.1%  
Dividends per share (Unadj.) Rs1.000-  
Dividend yield (eoy) %0.20-  
Book value per share (Unadj.) Rs213.053.9 395.0%  
Shares outstanding (eoy) m126.2070.45 179.1%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x2.10.4 508.3%   
Avg P/E ratio x28.9-1.4 -1,997.2%  
P/CF ratio (eoy) x16.6-2.6 -628.8%  
Price / Book Value ratio x2.62.1 121.1%  
Dividend payout %5.30-   
Avg Mkt Cap Rs m69,1208,067 856.9%   
No. of employees `00013.32.8 473.4%   
Total wages/salary Rs m7,3592,527 291.2%   
Avg. sales/employee Rs Th2,477.46,956.1 35.6%   
Avg. wages/employee Rs Th555.2902.5 61.5%   
Avg. net profit/employee Rs Th180.6-1,993.0 -9.1%   
INCOME DATA
Net Sales Rs m32,83619,477 168.6%  
Other income Rs m418407 102.7%   
Total revenues Rs m33,25419,884 167.2%   
Gross profit Rs m4,5051,103 408.6%  
Depreciation Rs m1,7772,519 70.6%   
Interest Rs m2405,227 4.6%   
Profit before tax Rs m2,905-6,236 -46.6%   
Minority Interest Rs m020 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0511 0.0%   
Tax Rs m511-125 -408.2%   
Profit after tax Rs m2,394-5,580 -42.9%  
Gross profit margin %13.75.7 242.3%  
Effective tax rate %17.62.0 876.3%   
Net profit margin %7.3-28.7 -25.4%  
BALANCE SHEET DATA
Current assets Rs m19,45511,014 176.6%   
Current liabilities Rs m10,07632,060 31.4%   
Net working cap to sales %28.6-108.1 -26.4%  
Current ratio x1.90.3 562.0%  
Inventory Days Days9895 103.2%  
Debtors Days Days6734 199.5%  
Net fixed assets Rs m20,26029,440 68.8%   
Share capital Rs m252705 35.8%   
"Free" reserves Rs m26,6332,043 1,303.9%   
Net worth Rs m26,8863,800 707.5%   
Long term debt Rs m2,3409,018 25.9%   
Total assets Rs m41,17346,510 88.5%  
Interest coverage x13.1-0.2 -6,780.9%   
Debt to equity ratio x0.12.4 3.7%  
Sales to assets ratio x0.80.4 190.4%   
Return on assets %6.4-0.8 -841.8%  
Return on equity %8.9-146.9 -6.1%  
Return on capital %10.8-3.7 -288.2%  
Exports to sales %47.637.9 125.8%   
Imports to sales %14.922.6 65.7%   
Exports (fob) Rs m15,6427,378 212.0%   
Imports (cif) Rs m4,8844,406 110.8%   
Fx inflow Rs m15,6427,513 208.2%   
Fx outflow Rs m4,8845,649 86.5%   
Net fx Rs m10,7591,865 577.0%   
CASH FLOW
From Operations Rs m3,4111,682 202.8%  
From Investments Rs m-1,354-9,860 13.7%  
From Financial Activity Rs m-1,3046,644 -19.6%  
Net Cashflow Rs m753-1,535 -49.1%  

Share Holding

Indian Promoters % 45.9 32.3 142.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.4 4.6 247.8%  
FIIs % 25.3 3.3 766.7%  
ADR/GDR % 0.0 4.6 -  
Free float % 17.4 55.3 31.5%  
Shareholders   36,892 84,811 43.5%  
Pledged promoter(s) holding % 2.1 54.9 3.9%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   FRESENIUS KABI ONCO.  DIVIS LABORATORIES  FULFORD INDIA  ALEMBIC PHARMA  AJANTA PHARMA  

Compare IPCA LABS With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps 470 Points; Energy and Banking Stocks Witness Selling(Closing)

Indian share markets witnessed negative trading activity throughout the day and ended deep in the red. The BSE Sensex fell over 550 points intraday and breached the 36,000 mark.

Related Views on News

IPCA LABS Announces Quarterly Results (1QFY20); Net Profit Up 101.5% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 101.5% YoY). Sales on the other hand came in at Rs 10 bn (up 18.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (4QFY19); Net Profit Up 113.4% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 113.4% YoY). Sales on the other hand came in at Rs 8 bn (up 6.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (3QFY19); Net Profit Up 51.7% (Quarterly Result Update)

Feb 14, 2019 | Updated on Feb 14, 2019

For the quarter ended December 2018, IPCA LABS has posted a net profit of Rs 2 bn (up 51.7% YoY). Sales on the other hand came in at Rs 9 bn (up 10.3% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

ORCHID PHARMA LTD Announces Quarterly Results (2QFY19); Net Profit Up 67.1% (Quarterly Result Update)

Jan 31, 2019 | Updated on Jan 31, 2019

For the quarter ended September 2018, ORCHID PHARMA LTD has posted a net profit of Rs 231 m (up 67.1% YoY). Sales on the other hand came in at Rs 1 bn (down 31.9% YoY). Read on for a complete analysis of ORCHID PHARMA LTD's quarterly results.

IPCA LABS Announces Quarterly Results (2QFY19); Net Profit Up 24.1% (Quarterly Result Update)

Nov 15, 2018 | Updated on Nov 15, 2018

For the quarter ended September 2018, IPCA LABS has posted a net profit of Rs 1 bn (up 24.1% YoY). Sales on the other hand came in at Rs 10 bn (up 15.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Sep 19, 2019 (Close)

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

IPCA LABS - PIRAMAL ENTERPRISES COMPARISON

COMPARE IPCA LABS WITH

MARKET STATS